Učitavanje...
Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence
Sunitinib is a multitarget tyrosine kinase inhibitor endowed mainly by antiangiogenic effects, although an indirect inhibitory effect on tumor growth and, more recently, a complex activity on antitumor immune response has been described. From approval by the US Food and Drug Administration (FDA) in...
Spremljeno u:
| Izdano u: | Ther Adv Urol |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
SAGE Publications
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5896861/ https://ncbi.nlm.nih.gov/pubmed/29662544 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287217713902 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|